Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nikolai Paul Pace has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The European Health Data Space and biobanking in Europe: synergies, tensions and the future governance of data-driven health research

    by Laura Grech, Nikolai Paul Pace

    The European Health Data Space (EHDS) represents the most ambitious attempt to date to create a common legal, technical and governance framework for the use of health data across the European Union. Its adoption creates a new infrastructure for both primary use, focusing on cross-border access to electronic health records for care, and secondary use, centred on research, innovation, public health, regulatory science and policymaking. In parallel, European biobanking has matured into a core research infrastructure supporting genomic medicine, biomarker discovery, rare disease research and precision public health. The convergence of EHDS-enabled electronic health records, BBMRI-ERIC-associated biobanks, and the 1+ Million Genomes initiative offers a plausible route towards federated, large-scale, molecularly informed health systems in Europe. This article critically examines that opportunities and challenges arising from this convergence. It argues that the EHDS and biobanking are complementary but not automatically interoperable. Biobanks provide depth: biospecimens, molecular assays, longitudinal cohorts and consented research infrastructures. The EHDS provides breadth: population-scale clinical trajectories, regulatory gateways, Health Data Access Bodies and Secure Processing Environments. The 1+ Million Genomes and Genomic Data Infrastructure initiatives provide a genomics-specific federated layer that may connect these ecosystems through standards such as GA4GH, Beacon, Phenopackets and FHIR-Genomics. However, substantial obstacles remain. These include uneven digital maturity across Member States, immature representation of biospecimen and omics metadata in clinical data models, unresolved interactions between EHDS opt-out mechanisms and biobank consent, fragmented national interpretations of the GDPR, sustainability constraints, environmental costs of petabyte-scale computing, and the risk that artificial intelligence trained on biased or incomplete datasets will reproduce health inequities. We argue that EHDS-biobank integration should not be regarded solely as a technical exercise. Rather, it represents a governance challenge involving trust, reciprocity, legal interpretation, standards development, infrastructure investment and public legitimacy. Without coordinated action, the EHDS may create a formally integrated yet substantively unequal data ecosystem. Conversely, with deliberate design and effective governance, it has the potential to provide Europe with a trustworthy, federated and clinically actionable research infrastructure.

  • Open Access

    Rethinking scale in AI-driven genomic medicine – The role of small biobanks

    by Laura Grech, Nikolai Paul Paul Pace

    Artificial intelligence is rapidly advancing genomic medicine, but its clinical trustworthiness cannot be secured by larger datasets alone. This perspective argues that small biobanks, including national, regional, hospital-linked and disease-focused collections provide essential stress tests for AI-driven genomic medicine because they expose failures in population calibration, rare-variant interpretation, phenotype realism, privacy protection, and governance. Rather than serving primarily as substrates for training general-purpose models, small biobanks are most valuable as environments for external validation, local calibration, interpretability, federated analysis, and accountable deployment. Their local representativeness, clinical linkage, and governance structures can help determine whether AI predictions remain valid and clinically useful outside the large datasets on which they were developed. Trustworthy AI-powered genomic medicine will therefore depend not only on larger models and larger datasets, but also on smaller, well-governed biobanks that force those models to prove their validity in real-world settings.


  • Open Access

    Telomere Length in Metabolic Syndrome: Mechanisms, Epidemiology and Clinical Implications: A Narrative Review

    by Kyle Cilia, Zachary Gauci, Rachel Agius, Stephen Fava, Nikolai Pace

    Metabolic syndrome (MetS) is a major and growing global public health challenge, affecting a substantial proportion of adults worldwide and contributing markedly to the rising burden of type 2 diabetes, cardiovascular disease, metabolic dysfunction-associated steatotic liver disease, and premature mortality. Despite its high prevalence and systemic consequences, the biological mechanisms linking chronic metabolic stress to cellular ageing remain incompletely resolved. Telomere length (TL), particularly leukocyte telomere length (LTL), has emerged as a candidate integrative biomarker of biological ageing, cumulative metabolic injury, and disease risk; however, the field remains limited by heterogeneous study designs, inconsistent measurement approaches, conflicting genetic data, and uncertainty regarding whether TL is merely a correlate of metabolic dysfunction or a clinically informative biomarker and mechanistic mediator. This narrative review synthesizes evidence on the epidemiology, mechanistic basis, and clinical implications of TL variation in obesity and MetS, with emphasis on human population studies. It specifically addresses the current gap between observational associations and biological interpretation by integrating epidemiological, longitudinal, mechanistic, and Mendelian randomization data within a unified framework. Across large cohorts and meta-analyses, MetS and several of its component traits are generally associated with shorter LTL. Shorter LTL in MetS appears to identify individuals at higher risk of adverse outcomes, including all-cause and cardiovascular mortality. Mechanistically, oxidative stress, chronic low-grade inflammation, mitochondrial dysfunction, hormonal perturbation, and genetic and epigenetic regulation of telomere-maintenance pathways emerge as interconnected drivers of accelerated telomere attrition and cellular senescence. Mendelian randomization studies indicate a more complex architecture, in which adiposity-related traits may causally shorten LTL, whereas genetically longer LTL may associate with selected adverse metabolic phenotypes, consistent with pleiotropy, tissue specificity, and pathway-dependent effects. This review collates the current evidence, highlights major research gaps, and outlines the methodological and biological advances needed to determine whether TL can serve as a clinically actionable biomarker or therapeutic target in MetS.


  • Open Access

    Investigating the Inflammatory Link Between Vitamin D and Hidradenitis Suppurativa: A Systematic Review and Causal Inference Analysis

    by Jasmine Spiteri, Laura Grech, Dillon Mintoff, Nikolai P. Pace

    An inverse correlation between serum vitamin D levels and hidradenitis suppurativa (HS) severity is frequently reported, yet the causal nature and direction of this association remain unresolved. A systematic review was conducted following PRISMA guidelines, identifying 12 relevant studies. A two-sample Mendelian randomization (MR) analysis using the inverse-variance weighted (IVW) method was subsequently performed using genetic instruments for vitamin D from the UK Biobank (n = 417,580) and HS summary statistics from FinnGen (n = 1420). The systematic review confirmed a high prevalence of vitamin D deficiency (−1) among HS patients (weighted mean 17.90 ng mL−1) and identified inverse correlations between vitamin D levels and disease severity, active lesions, and C-reactive protein (CRP), while supplementation improved clinical outcomes. A null MR estimate consistent with the absence of a detectable average linear causal effect of lifelong genetically predicted 25(OH)D levels on HS risk in the analyzed population was observed. Sensitivity analyses yielded consistent null results with no significant horizontal pleiotropy. The results suggest that hypovitaminosis D is likely a marker of the systemic inflammatory state rather than a direct causative factor. The observed clinical benefits of vitamin D supplementation warrant further interventional studies to define its potential therapeutic role.

  • Open Access

    Frequency and Spectrum of Actionable Secondary Findings in the Maltese Population

    by Laura Grech, Celine Ann Grech, Jasmine Spiteri, Dillon Mintoff, Nikolai Paul Pace

    Background: The identification of actionable secondary findings (SFs) through clinical exome sequencing has become increasingly relevant with the integration of genomics into routine healthcare. The frequency and spectrum of these findings vary across populations.Methods: We analyzed exome sequencing data from 350 unrelated Maltese individuals, comprising 320 pseudonymised controls and 30 participants from the pilot sequencing phase of the national biobank DwarnaBio, to assess the prevalence of pathogenic or likely pathogenic (P/LP) variants in the ACMG SF v3.2 gene list. All samples underwent uniform sequencing, rigorous quality control, and variant interpretation according to ACMG/AMP guidelines.Results: Actionable P/LP variants were identified in 12 individuals (3.4%) across autosomal dominant genes, predominantly associated with inherited cardiac conditions and cancer predisposition syndromes. These findings highlight the importance of including underrepresented populations in genomic research and emphasize the need to establish provisions for the return of clinically actionable results to biobank participants, supported by access to genetic counseling.Conclusion: Our results advocate for the integration of population‐specific genomic data into national precision medicine frameworks, particularly for small or isolated populations where tailored approaches to variant curation and clinical translation are required. This study provides the first baseline estimate of actionable SFs in the Maltese population and offers insights for advancing precision medicine frameworks.


  • Open Access

    Transcriptomic Signatures and Molecular Pathways in Hidradenitis Suppurativa—A Narrative Review

    by Jasmine Spiteri, Dillon Mintoff, Laura Grech, Nikolai P. Pace

    Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory dermatosis of the pilosebaceous unit characterized by nodules, abscesses, and dermal tunnels. Recent transcriptomic studies have implicated dysregulation of innate and adaptive immune responses, epidermal barrier dysfunction, and systemic metabolic alterations. This review synthesizes findings from 16 studies investigating the HS transcriptome using bulk and single-cell RNA sequencing. Differential gene expression analyses revealed extensive upregulation of inflammatory cytokines and chemokines, particularly in lesional and perilesional skin. These changes were also mirrored in non-lesional skin, suggesting diffuse immune dysregulation beyond visibly affected areas. Downregulated pathways include those involved in lipid metabolism, muscle contraction, and neuronal signaling, potentially linking HS to obesity, metabolic syndrome, and neuropsychiatric comorbidities. Single-cell transcriptomics confirmed the enrichment of keratinocytes and immune cells (B cells, plasma cells, M1 macrophages, and T cells) with proinflammatory profiles in HS lesions. Keratinocyte dysfunction further implicated a compromised epidermal barrier in disease pathogenesis. While transcriptomic studies have advanced mechanistic understanding and highlighted therapeutic targets—such as the IL-1β–TH17 axis and B cell signaling pathways—methodological heterogeneity limits cross-study comparisons. Integration of multi-omics data and standardized phenotyping will be essential to identify robust biomarkers, stratify HS subtypes, and guide personalized therapeutic approaches.


  • Biobanking and gynecologic oncology - Special considerations, challenges and opportunities

    by Laura Grech, Celine Ann Grech, Jean Calleja-Agius, Nikolai Paul Pace


  • Serum Immunoglobulin G Levels and Nicastrin Variation in Hidradenitis Suppurativa

    by Dillon Mintoff, Nikolai P. Pace

    Importance: Variation in nicastrin (NCSTN) is associated with a monogenic subtype of hidradenitis suppurativa. Dysregulation of humoral immunity has been suggested as a potential mechanistic link between NCSTN variation and hidradenitis suppurativa. There is a paucity of biomarkers that can predict disease-associated variation.Objective: To investigate whether serum immunoglobulin levels, as a surrogate marker of humoral immunity, can identify individuals with hidradenitis suppurativa who have a specific disease-associated NCSTN variant.Design, Setting, and Participants: Maltese individuals with hidradenitis suppurativa genotyped for a disease-associated NCSTN in-frame deletion prevalent in the local patient cohort were invited to participate in this cross-sectional study from January to July 2023. Participation was restricted to adult individuals with hidradenitis suppurativa without known or suspected pathologies that would be associated with serum immunoglobulin levels. Data were analyzed between October 2023 and December 2023.Exposure: Serum immunoglobulin G levels and other hematological paraments were analyzed.Main Outcome and Measure: Main outcomes were the associations between serum immunoglobulin levels and an underlying NCSTN variation in individuals with hidradenitis suppurativa.Results: A total of 125 individuals (64 female individuals [51.2%]) with hidradenitis suppurativa of Maltese ethnicity were recruited in the study, of whom 17 (13.6%) who were from 7 genealogically unrelated families were heterozygous for the disease-associated NCSTN variant. Deletion carriers had a higher serum immunoglobulin G level (1370 mg/dL vs 1140 mg/dL [to convert to g/L, multiply by 0.01]; P < .001). The association between NCSTN variation and elevated immunoglobulin G levels retained significance despite adjusting for multiple confounders, including markers of disease severity, age of recruitment, age of disease onset, treatment with adalimumab, and liver transaminase levels. Serum immunoglobulin G demonstrated a strong discriminatory capacity in identifying patients who were heterozygous for the NCSTN variant.Conclusion and Relevance: The results of this cross-sectional study suggest an altered humoral immune state in patients harboring a specific NCSTN variant and support the role of serum immunoglobulin G levels as a potential predictive biomarker of monogenic hidradenitis suppurativa. This may aid in identifying and prioritizing individuals with monogenic hidradenitis suppurativa.

  • Intrahepatic Cholestasis of Pregnancy: A Single‐Centre Whole‐Exome Sequencing Study in a Maltese Cohort

    by Dorianne Spiteri, Laura Grech, Charles Savona‐Ventura, Nikolai Paul Pace

    Intrahepatic cholestasis of pregnancy (ICP) has a multifactorial pathophysiology involving genetic, endocrine, and environmental factors. It is associated with maternal distress and adverse foetal outcomes. The monogenic aetiology of ICP remains unexplored in the Maltese population. We apply whole exome sequencing in 20 unrelated index cases to assess the molecular spectrum of variants in genes linked to bile acid transport. We shortlisted five unique heterozygous variants. Three ABCB4 variants, including a novel likely pathogenic stop‐gain variant were detected. Three genealogically unrelated cases carried an ABCB4 p.Asn510Ser variant, suggestive of a founder through shared haplotype analysis. This study provides preliminary insight into the monogenic aetiology of ICP from an unstudied population. It expands the spectrum of genetic variants associated with ICP and provides evidence for a founder effect in the Maltese population.